Assembly Biosciences ASMB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's cash & equivalents?
- Assembly Biosciences (ASMB) reported cash & equivalents of $31.12M in Q1 2026.
- How has Assembly Biosciences's cash & equivalents changed year-over-year?
- Assembly Biosciences's cash & equivalents increased by 32.9% year-over-year, from $23.41M to $31.12M.
- What is the long-term trend for Assembly Biosciences's cash & equivalents?
- Over 5 years (2020 to 2025), Assembly Biosciences's cash & equivalents has grown at a -0.3% compound annual growth rate (CAGR), from $59.44M to $58.45M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.